Physician profile
Deborah Kim
NPI 1679830954
$8,188.59
in general payments reported to CMS, 2019-2025
29 companies · $3,108 in 2025
The $3,108 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $57.06 · 2021: $17.27 · 2022: $377 · 2023: $1,891 · 2024: $2,046 · 2025: $3,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,952 · Education: $93.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,952.13 |
| Education | $93.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,511.62 | 2019-2025 | Tremfya, Remicade, Stelara |
| Amgen INC. | $1,156.72 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Abbvie INC. | $763.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $712.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $639.41 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $528.85 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $449.64 | 2019-2025 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $442.50 | 2023-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $402.51 | 2025 | Sovuna, Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $297.12 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $185.98 | 2024-2025 | Orencia |
| Pfizer INC. | $178.34 | 2019-2025 | |
| Lilly USA, LLC | $131.86 | 2019-2023 | Taltz |
| Janssen Pharmaceuticals, INC | $116.44 | 2025 | Tremfya |
| Genentech USA, INC. | $100.57 | 2019-2025 | Actemra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $87.47 | 2023-2025 | Strensiq |
| Genzyme Corporation | $70.85 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $69.06 | 2023-2024 | Iovera, Zilretta |
| Scilex Pharmaceuticals INC. | $57.37 | 2021-2024 | Ztlido |
| Celgene Corporation | $42.28 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.70 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $37.03 | 2024-2025 | Idacio |
| Invivyd INC | $30.28 | 2025 | Pemgarda |
| Sandoz INC. | $27.83 | 2025 | Hyrimoz |
| Merck Sharp & Dohme LLC | $26.35 | 2019 | |
| Saluda Medical Americas, INC. | $23.75 | 2025 | Evoke |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.89 | 2023 | |
| Celltrion USA INC. | $19.88 | 2023 | Yuflyma |
| Radius Health, INC. | $18.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.